Hsp70 based combination therapy
AssigneeMultimmune GmbH
InventorGabriele Multhoff
Life of this patent
Estimating the term…
Abstract
Provided are combination therapies for treating and preventing relapse of a tumor and infectious diseases in a subject, as well as methods for use thereof. The combination therapies comprise an Hsp70 based pharmaceutical ingredient and at least one further immunotherapeutic agent that specifically inhibits and/or preferably binds to an immune checkpoint molecule or tumor immune microenvironment immune regulator. Furthermore, a kit and methods of using the combination therapies of the invention are described.
Claims18
A method of treating or preventing relapse of a tumor in a subject in need thereof, comprising administering to the subject:
- (a) peripheral blood mononuclear cells (PBMCs) or a fraction thereof comprising natural killer (NK) cells, activated in vitro or ex vivo by a derivative of an Hsp70 protein, which is not complexed with peptides of tumor cells,
- wherein the Hsp70 protein derivative is a peptide of 30 or less amino acids,
- wherein the peptide comprises TKDNNLLGRFELSG (SEQ ID NO:
- 2), and
- wherein the peptide stimulates NK cell activity in combination with interleukin-2 (IL-2);
- and
- (b) a therapeutically effective amount of a monoclonal anti-PD1 antibody;
- wherein the tumor is a carcinoma and expresses cell surface Hsp70, and
- wherein the subject is suffering from or has been treated for non-small cell lung carcinoma (NSCLC).
A method of treating or preventing relapse of a tumor, wherein the tumor is a carcinoma expressing cell surface Hsp70 in a subject who received a treatment comprising peripheral blood mononuclear cells (PBMCs) or a fraction thereof comprising natural killer (NK) cells, activated in vitro or ex vivo by a derivative of an Hsp70 protein, which is not complexed with peptides of tumor cells, wherein the Hsp70 protein derivative is a peptide of 30 or less amino acids, wherein the peptide comprises TKDNNLLGRFELSG (SEQ ID NO:
- 2), and wherein the peptide stimulates NK cell activity in combination with interleukin-2 (IL-2),
- the method comprising:
- administering to the subject a therapeutically effective amount of a monoclonal anti-PD1 antibody in combination with a conventional anti-tumor treatment, wherein the conventional anti-tumor treatment is radiochemotherapy with carboplatin or cisplatin, and wherein the subject is suffering from or has been treated for non-small cell lung carcinoma (NSCLC).
Dependencies are inferred from the claim text.